



BIBLIOGRAFÍA CLÍNICA

SOBRE INDICACIONES TERAPÉUTICAS



Straumann® Emdogain

COMMITTED TO
SIMPLY DOING MORE
FOR DENTAL PROFESSIONALS

ÍNDICE

1 Principios básicos de la regeneración periodontal con proteínas de la matriz del esmalte	2
<hr/>	
2 Straumann® Emdogain en defectos intraóseos	5
2.1 Artículos de revisión bibliográfica	5
2.2 Estudios clínicos controlados	5
2.3 Casos clínicos	6
2.4 Straumann® Emdogain y la regeneración tisular guiada (GTR)	9
<hr/>	
3 Straumann® Emdogain en defectos de furcación	10
3.1 Estudios clínicos con defectos de furcación	10
<hr/>	
4 Straumann® Emdogain en defectos de recesión	11
4.1 Estudios y casos clínicos con defectos de recesión	11
<hr/>	
5 Straumann® Emdogain con material para injerto óseo	13
<hr/>	

1 PRINCIPIOS BÁSICOS DE LA REGENERACIÓN PERIODONTAL CON PROTEÍNAS DE LA MATRIZ DEL ESMALTE

El principal objetivo del tratamiento reconstructivo periodontal es salvar los dientes. La mejor forma de lograrlo es la regeneración de un soporte funcional pleno.

Las proteínas de la matriz del esmalte son responsables del desarrollo del cemento y el ligamento periodontal en la fase de desarrollo del diente⁸. Al aplicarlas a la superficie radicular limpia del diente con enfermedad periodontal, el periodonto – que incluye el cemento, el ligamento periodontal y el hueso alveolar– es regenerado^{1, 2, 3, 4, 5, 105} imitando los procesos biológicos del desarrollo natural del diente^{13, 14}.



Straumann® Emdogain se distribuye uniformemente y se precipita sobre la superficie radicular para formar una matriz extracelular.



Straumann® Emdogain estimula la atracción y proliferación de células mesenquimales desde la parte sana del periodonto.




Se segregan citoquinas naturales y específicas, así como sustancias autocrinas, lo que promueve la proliferación necesaria.

Straumann® Emdogain está formado por una mezcla de proteínas de la matriz del esmalte y sus derivados^{6, 9} (EMD) con alginato de propilenglicol (PGA) como portador. La proteína más prevalente –la amelogénina– y sus derivados pueden ser también el factor más importante en la actividad regenerativa de EMD.⁷



*Atracción y diferenciación a cemento-
blastos, que comienzan con la formación
de la matriz de cemento donde se fijarán
las fibras periodontales.*



*La capa de cemento de nueva formación
aumenta de grosor. Las fibras de ligamento
periodontal se anclan a la superficie
radicular.*



*En unos meses, el defecto se rellena con
tejido periodontal de nueva formación.*



*Crece nuevo hueso alveolar sobre la capa
de cemento y en el hueco del defecto.*



*Straumann® Emdogain regenera la
compleja estructura dental del periodonto,
estableciendo un nuevo soporte funcional.*

Cuando se aplica Straumann® Emdogain se precipitan proteínas EMD desde el PGA portador sobre la superficie radicular. Este proceso de precipitación tiene lugar inmediatamente debido al aumento del pH y de la temperatura, y las proteínas EMD forman una matriz extracelular sobre la superficie radicular^{12, 14}. Esta matriz influye en la fijación¹¹ y proliferación¹⁰ celulares y ejerce un papel mediador en la formación de cemento sobre la raíz, lo que proporciona una base para todos los tejidos necesarios asociados a un verdadero soporte funcional.

1. Pimentel SP, et al. Enamel matrix derivative versus guided tissue regeneration in the presence of nicotine: a histomorphometric study in dogs.
J Clin Periodontol. 2006;33:900–907.
2. Bosshardt DD, et al. Effects of enamel matrix proteins on tissue formation along the roots of human teeth.
J Periodontol Res. 2005;40:158–167.
3. Sallum EA, et al. Enamel matrix derivative and guided tissue regeneration in the treatment of dehiscence-type defects: a histomorphometric study in dogs.
J Periodontol. 2004;75:1357–1363.
4. Sakallioğlu U, et al. Healing of periodontal defects treated with enamel matrix proteins and root surface conditioning – an experimental study in dogs.
Biomaterials. 2004;25:1831–1840.
5. Cochran DL, et al. The effect of enamel matrix proteins on periodontal regeneration as determined by histological analyses.
J Periodontol. 2003;74:1043–1055.
6. Veis A, et al. Amelogenin gene splice products: potential signalling molecules.
Cell Mol Life Sci. 2003;60:38–55.
7. Maycock J, et al. Characterization of a porcine amelogenin preparation, Emdogain, a biological treatment for periodontal disease.
Connect Tissue Res. 2002;43:472–476.
8. Sculean A, et al. Presence of an enamel matrix protein derivative on human teeth following periodontal surgery.
Clin Oral Investig. 2002;6:183–187.
9. Zeichner-David M. Is there more to enamel matrix proteins than biomineralization?
Matrix Biol. 2001;20:307–316.
10. Lyngstadaas S, et al. Autocrine growth factors in human periodontal ligament cells cultured on enamel matrix derivative.
J Clin Periodontol. 2001;28(2):181–188.
11. Gestrelius S, et al. In vitro studies on periodontal ligament cells and enamel matrix derivative.
J Clin Periodontol. 1997;24(9):685–692.
12. Gestrelius S, et al. Formulation of enamel matrix derivative for surface coating. Kinetics and cell colonization.
J Clin Periodontol. 1997;24:678–684.
13. Hammarström L. Enamel matrix, cementum development and regeneration.
J Clin Periodontol. 1997;24:658–668.
14. Hammarström L, et al. Periodontal regeneration in a buccal dehiscence model in monkeys after application of enamel matrix proteins.
J Clin Periodontol. 1997;24:669–677.

2 STRAUMANN® EMDOGAIN EN DEFECTOS INTRAÓSEOS

El objetivo último del tratamiento periodontal es la conservación de los dientes. Si bien el desbridamiento con colgajo abierto (OFD por sus siglas inglesas) repara el defecto periodontal, con el consiguiente aumento de la tasa de supervivencia, el uso adicional de Straumann® Emdogain regenera el tejido periodontal y mejora significativamente el resultado clínico^{15, 16, 17, 18}. El beneficio clínico del procedimiento reside en la estabilidad a largo plazo del tejido periodontal regenerado, que se refleja en estudios^{19, 31, 36, 62} realizados durante un periodo de hasta 9 años³¹.

El uso de Straumann® Emdogain mejora significativamente varios parámetros clínicos en comparación con el empleo de OFD únicamente: reducción de la profundidad de sondaje (PPD)^{19, 20, 21, 22, 23, 24, 25, 27, 28, 29}, nivel de soporte clínico (CAL)^{19, 20, 21, 22, 23, 24, 25, 27, 28, 29}, sangrado al sondaje (BP)²⁸, y nivel de rellenado de hueso, medido como densidad ósea radiográfica^{19, 28, 29, 94} o en el momento de la reintervención^{27, 36}. Además, también se ha observado una mejora en la capacidad masticatoria de los pacientes²¹. La probabilidad de alcanzar una mejora significativa de los resultados clínicos demostró duplicarse²⁵ mediante Straumann® Emdogain. Numerosos casos clínicos³¹⁻⁶¹, que incluyen datos histológicos^{37, 54, 55, 75} apoyan estas conclusiones. Factores clínicos como el ángulo del defecto³⁹, el tabaquismo, la higiene oral y la edad⁷¹ influyen en el resultado.

Straumann® Emdogain es fácil de usar y seguro. En aplicaciones únicas o múltiples en combinación con cirugía periodontal ofrece la flexibilidad de tratar zonas difíciles.^{30, 38, 53}

2.1 Artículos de revisión bibliográfica

15. Sculean A, et al. The application of enamel matrix protein derivate (Emdogain) in regenerative periodontal therapy: a review. *Med Princ Pract.* 2007;16:167-180.
16. Esposito M, et al. Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defects. *Cochrane Database Syst Rev.* 2003;2:CD003875. Update in: *Cochrane Database Syst Rev.* 2005;4: CD003875.
17. Trombelli L. Which reconstructive procedures are effective for treating the periodontal intraosseous defect? *Periodontol 2000.* 2005;37:88-105.
18. Venezia E, et al. The use of enamel matrix derivative in the treatment of periodontal defects: a literature review and meta-analysis. *Crit Rev Oral Biol Med.* 2004;15(6):382-402.

2.2 Estudios clínicos controlados

19. Heden G, et al. Five-year follow-up of regenerative periodontal therapy with enamel matrix derivative at sites with angular bone defects. *J Periodontol.* 2006;77:295-301.
20. Francetti L, et al. Evaluation of efficacy of enamel matrix derivative in the treatment of intrabony defects: a 24-month multicenter study. *Int J Periodontics Restorative Dent.* 2005;25(5): 461-473.
21. Tonetti MS, et al. Healing, post-operative morbidity and patient perception of outcomes following regenerative therapy of deep intrabony defects. *J Clin Periodontol.* 2004;31(12):1092-1098.
22. Francetti L, et al. Enamel matrix proteins in the treatment of intra-bony defects. A prospective 24-month clinical trial. *J Clin Periodontol.* 2004;31:52-59.

23. Wachtel H, et al. Microsurgical access flap and enamel matrix derivative for the treatment of periodontal intrabony defects: a controlled clinical study. *J Clin Periodontol.* 2003;30(6):496–504.
24. Yilmaz S, et al. Enamel matrix proteins in the treatment of periodontal sites with horizontal type of bone loss. *J Clin Periodontol.* 2003;30:197–206.
25. Tonetti MS, et al. Enamel matrix proteins in the regenerative therapy of deep intrabony defects. *J Periodontol.* 2002;29:317–325.
26. Wennström JL, Lindhe J. Some effects of enamel matrix proteins on wound healing in the dento-gingival region. *J Clin Periodontol.* 2002;29(1):9–14.
27. Froum SJ, et al. A comparative study utilizing open flap debridement with and without enamel matrix derivative in the treatment of periodontal intrabony defects: A 12-month re-entry. *J Periodontol.* 2001;72:25–34.
28. Okuda K, et al. Enamel matrix derivative in the treatment of human intrabony osseous defects. *J Periodontol.* 2000;71(12):1821–1828.
29. Heijl L, et al. Enamel matrix derivative (Emdogain) in the treatment of intrabony periodontal defects. *J Clin Periodontol.* 1997;24:705–714.
30. Zetterström O, et al. Clinical safety of enamel matrix derivative (EMDOGAIN) in the treatment of periodontal defects. *J Clin Periodontol.* 1997;24:697–704.
31. Sculean A, et al. Nine-year results following treatment of intrabony periodontal defects with an enamel matrix derivative: report of 26 cases. *Int J Periodontics Restorative Dent.* 2007;27:221–229.
32. Cortellini P, et al. A minimally invasive surgical technique with an enamel matrix derivative in the regenerative treatment of intrabony defects: a novel approach to limit morbidity. *J Clin Periodontol.* 2007;34:87–93.
33. Zucchelli G, et al. The papilla amplification flap for the treatment of a localized periodontal defect associated with a palatal groove. *J Periodontol.* 2006;77:1788–1796.
34. Harrel SK, et al. Prospective assessment of the use of enamel matrix proteins with minimally invasive surgery. *J Periodontol.* 2005;76:380–384.
35. Cortellini P, Tonetti MS. Clinical performance of a regenerative strategy for intrabony defects: scientific evidence and clinical experience. *J Periodontol.* 2005;76:341–350.
36. Rasperini G, et al. Long-term clinical observation of treatment of intrabony defects with enamel matrix derivative (Emdogain): surgical reentry. *Int J Periodontics Restorative Dent.* 2005;25(2):121–127.
37. Majzoub Z, et al. Two patterns of histologic healing in an intrabony defect following treatment with enamel matrix derivative: a human case report. *Int J Periodontics Restorative Dent.* 2005;25(3): 283–294.

2.3 Casos clínicos

38. Froum S, et al. A multicenter study evaluating the sensitization potential of enamel matrix derivative after treatment of two intrabony defects.
J Periodontol. 2004;75:1001–1008.
39. Tsitoura E, et al. Baseline radiographic defect angle of the intrabony defect as a prognostic indicator in regenerative periodontal surgery with enamel matrix derivative.
J Clin Periodontol. 2004;31:643–647.
40. Sculean A, et al. Five-year results following treatment of intrabony defects with enamel matrix proteins and guided tissue regeneration.
J Clin Periodontol. 2004;31:545–549.
41. Bonta H, et al. The use of enamel matrix protein in the treatment of localized aggressive periodontitis: a case report.
Quintessence Int. 2003;34:247–252.
42. Kiernicka M, et al. Use of Emdogain enamel matrix proteins in the surgical treatment of aggressive periodontitis.
Ann Univ Mariae Curie Skłodowska [Med]. 2003;58:397–401.
43. Sculean A, et al. Four-year results following treatment of intrabony periodontal defects with an enamel matrix protein derivative: a report of 46 cases.
Int J Periodontics Restorative Dent. 2003;23(4):345–351.
44. Sculean A, et al. Immunohistochemical evaluation of matrix molecules associated with wound healing following treatment with an enamel matrix protein derivative in humans.
Clin Oral Investig. 2003;7:167–174.
45. Cardaropoli G, Leonhardt AS. Enamel matrix proteins in the treatment of deep intrabony defects.
J Periodontol. 2002;73:501–504.
46. Trombelli L, et al. Supracrestal soft tissue preservation with enamel matrix proteins in treatment of deep intrabony defects.
J Clin Periodontol. 2002;29:433–439.
47. Pietruska MD, et al. Clinical and radiographic evaluation of periodontal therapy using enamel matrix derivative (Emdogain).
Rocz Akad Med Białymst. 2001;46:198–208.
48. Sculean A, et al. Treatment of intrabony defects with enamel matrix proteins or bioabsorbable membranes. A 4-year follow-up split-mouth study.
J Periodontol. 2001;72:1695–1701.
49. Sculean A, et al. The effect of postsurgical antibiotics on the healing of intrabony defects following treatment with enamel matrix proteins.
J Periodontol. 2001;72:190–195.
50. Rethman MP. Treatment of a palatal-gingival groove using enamel matrix derivative.
Compend Contin Educ Dent. 2001;22:792–797.
51. Heden G. A case report study of 72 consecutive Emdogain-treated intrabony periodontal defects: clinical and radiographic findings after 1 year.
Int J Periodontics Restorative Dent. 2000;20:127–139.
52. Manor A, et al. Periodontal regeneration with enamel matrix derivative – case reports.
J Int Acad Periodontol. 2000;2:44–48.
53. Heard RH, et al. Clinical evaluation of wound healing following multiple exposures to enamel matrix protein derivative in the treatment of intrabony periodontal defects.
J Periodontol. 2000;71:1715–1721.

54. Sculean A, et al. Clinical and histologic evaluation of human intrabony defects treated with an enamel matrix protein derivative (Emdogain). *Int J Periodontics Restorative Dent.* 2000;20:374–381.
55. Yukna RA. Histologic evaluation of periodontal healing in humans following regenerative therapy with enamel matrix derivative. A 10-case series. *J Periodontol.* 2000;71:752–759.
56. Heden G, et al. Periodontal tissue alterations following Emdogain® treatment of periodontal sites with angular bone defects. A series of case reports. *J Clin Periodontol.* 1999;26:855–860.
57. Rasperini G, et al. Surgical technique for treatment of infrabony defects with enamel matrix derivative (Emdogain): 3 case reports. *Int J Periodontics Restorative Dent.* 1999;19:578–587.
58. Mellonig JT. Enamel matrix derivative for periodontal reconstructive surgery: technique and clinical and histologic case report. *Int J Periodontics Restorative Dent.* 1999;19(1):9–19.
59. Sculean A, et al. Treatment of intrabony periodontal defects with an enamel matrix protein derivative (Emdogain): a report of 32 cases. *Int J Periodontics Restorative Dent.* 1999;19:157–163.
60. Rasperini G, et al. Surgical technique for treatment of infrabony defects with enamel matrix derivative (Emdogain): 3 case reports. *Int J Periodontics Restorative Dent.* 1999;19:578–587.
61. Silvestri M, et al. Enamel matrix derivative in the treatment of infrabony defects. *Pract Periodontics Aesthet Dent.* 1999;11:615–618.

2.4 Straumann® Emdogain y la regeneración tisular guiada (GTR)

Las comparaciones directas entre la GTR y Straumann® Emdogain en defectos intraóseos demuestran que Straumann® Emdogain da lugar a una tasa mucho menor de complicaciones y morbilidad.^{62, 64, 67, 72} Los resultados clínicos con Straumann® Emdogain son al menos equivalentes^{62, 65, 68, 75} o mejores¹⁸. La estabilidad a largo plazo de los beneficios clínicos en comparación directa con la GTR ha sido objeto de seguimiento hasta un máximo de 8 años⁶². El uso adicional de una membrana en el tratamiento regenerador con Straumann® Emdogain no mejora el resultado, sino que aumenta las molestias posoperatorias del paciente⁶³.

62. Sculean A, et al. Treatment of intrabony defects with an enamel matrix protein derivative or bioabsorbable membrane: an 8-year follow-up split-mouth study. *J Periodontol.* 2006;77(11):1879–1886.
63. Sipos PM, et al. The combined use of enamel matrix proteins and a tetracycline-coated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects. *J Clin Periodontol.* 2005;32:765–772.
64. Sanz M, et al. Treatment of intrabony defects with enamel matrix proteins or barrier membranes: results from a multicenter practice-based clinical trial. *J Periodontol.* 2004;75:726–733.
65. Minabe M, et al. A comparative study of combined treatment with a collagen membrane and enamel matrix proteins for the regeneration of intraosseous defects. *Int J Periodontics Restorative Dent.* 2002;22:595–605.
66. Windisch P, et al. Comparison of clinical, radiographic, and histometric measurements following treatment with guided tissue regeneration or enamel matrix proteins in human periodontal defects. *J Periodontol.* 2002;73:409–417.
67. Zucchelli G, et al. Enamel matrix proteins and guided tissue regeneration with titanium-reinforced expanded polytetrafluoroethylene membranes in the treatment of infrabony defects: a comparative controlled clinical trial. *J Periodontol.* 2002;73:3–12.
68. Silvestri M, et al. Comparison of treatments of infrabony defects with enamel matrix derivative, guided tissue regeneration with a nonresorbable membrane and Widman modified flap. A pilot study. *J Clin Periodontol.* 2000;27:603–610.
69. Pontoriero R, et al. The use of barrier membranes and enamel matrix proteins in the treatment of angular bone defects. A prospective controlled clinical trial. *J Clin Periodontol.* 1999;26(12):833–840.
70. Sculean A, et al. Comparison of enamel matrix proteins and bioabsorbable membranes in the treatment of intrabony periodontal defects. A split-mouth study. *J Periodontol.* 1999;70:255–262.

3 STRAUMANN® EMDOGAIN EN DEFECTOS DE FURCACIÓN

En el tratamiento quirúrgico de la furcación de clase II, Straumann® Emdogain lleva a una regeneración significativa de las lesiones de furcación^{72,74}. Resultados de ensayos clínicos aleatorizados que comparan Straumann® Emdogain con una membrana reabsorbible en el tratamiento de furcaciones de clase II han demostrado una reducción significativa de la profundidad horizontal de furcación. Clínicamente, el tratamiento con Straumann® Emdogain redujo el 78% de los defectos. De ellos, la reducción fue completa en un 18%. En el tratamiento con membrana sólo pudo observarse una reducción de la furcación en el 67% de los defectos, y sólo fue completa en el 7% de éstos. Resultó evidente una menor incidencia de complicaciones posoperatorias tras el tratamiento con Straumann® Emdogain en comparación con la GTR. Al cabo de 1 semana de la operación, el 62% de los pacientes tratados con Straumann® Emdogain no presentaban dolor, frente a solo un 12% de los tratados con GTR. Además, un 44% no mostraba inflamación, frente a un 6% en el grupo de control con GTR^{72,73}. Además, en pacientes con factores limitantes como edad o mala higiene oral, el tratamiento de los defectos de furcación con Straumann® Emdogain resultó ser superior a la GTR⁷¹.

3.1 Estudios clínicos con defectos de furcación

71. Hoffmann T, et al. A randomized clinical multicentre trial comparing enamel matrix derivative and membrane treatment of buccal class II furcation involvement in mandibular molars. Part III: patient factors and treatment outcome.
J Clin Periodontol. 2006;33(8):575–583.
72. Jepsen S, et al. A randomized clinical trial comparing enamel matrix derivative and membrane treatment of buccal class II furcation involvement in mandibular molars. Part I: study design and results for primary outcomes.
J Periodontol. 2004;75:1150–1160.
73. Meyle J, et al. A randomized clinical trial comparing enamel matrix derivative and membrane treatment of buccal class II furcation involvement in mandibular molars. Part II: secondary outcomes.
J Periodontol. 2004;75:1188–1195.
74. Donos N, et al. Clinical evaluation of an enamel matrix derivative in the treatment of mandibular degree II furcation involvement: a 36-month case series.
Int J Periodontics Restorative Dent. 2003;23(5): 507–512.
75. Donos N, et al. Wound healing of degree III furcation involvements following guided tissue regeneration and/or Emdogain. A histologic study.
J Clin Periodontol. 2003;30:1061–1068.

4 STRAUMANN® EMDOGAIN EN DEFECTOS DE RECESIÓN

El tratamiento de superficies radiculares expuestas es una cuestión cada vez más importante. Esto se ve impulsado por el aumento de las exigencias estéticas de los pacientes.

Para el paciente y el profesional, la estabilidad a largo plazo de la cobertura del defecto es un criterio riguroso de éxito. Straumann® Emdogain se ha utilizado con éxito para mejorar los parámetros clínicos de la técnica de colgajo coronal avanzado (CAF)⁸⁷. En superficies radiculares anteriormente expuestas tratadas con CAF, la adición de Straumann® Emdogain mejora significativamente los parámetros clínicos, incluidas la cobertura de la raíz^{77, 80, 83, 84, 85}, la calidad y cantidad de tejido (p.ej. tejido queratinizado^{76, 77, 80, 83, 84, 85, 91}) y la estabilidad a largo plazo⁸¹ después de intervenciones de cobertura de la recesión.

La combinación de CAF con Straumann® Emdogain muestra una cobertura completa de la raíz en un 89,5% de los casos frente a un 79% al utilizar una combinación de CAF con injerto de tejido conjuntivo (CTG)⁸⁷. La técnica combinada con Straumann® Emdogain presenta menos complicaciones y es menos dolorosa para el paciente^{87, 85} al evitar una segunda herida quirúrgica. También se han obtenido pruebas histológicas de la regeneración periodontal, con nuevo cemento, nuevo hueso y fibras de tejido conjuntivo^{92, 88} en el tratamiento combinado de CAF y Straumann® Emdogain.

4.1 Estudios y casos clínicos con defectos de recesión

76. Shin SH, et al. A comparative study of root coverage using a cellular dermal matrix with and without enamel matrix derivative. *J Periodontol.* 2007;78:411–421.
77. Piloni A, et al. Root coverage with a coronally positioned flap used in combination with enamel matrix derivative: 18-month clinical evaluation. *J Periodontol.* 2006;77:2031–2039.
78. Sato S, et al. Treatment of Miller class III recessions with enamel matrix derivative (Emdogain) in combination with subepithelial connective tissue grafting. *Int J Periodontics Restorative Dent.* 2006;26(1):71–77.
79. Moses O, et al. Comparative study of two root coverage procedures: a 24-month follow-up multi-center study. *J Periodontol.* 2006;77(2):195–202.
80. Castellanos A, et al. Enamel matrix derivative and coronal flaps to cover marginal tissue recessions. *J Periodontol.* 2006;77(1):7–14.
81. Spahr A, et al. Coverage of Miller class I and II recession defects using enamel matrix proteins versus coronally advanced flap technique: a 2-year report. *J Periodontol.* 2005;76(11):1871–1880.
82. Berlucchi I, et al. The influence of anatomical features on the outcome of gingival recessions treated with coronally advanced flap and enamel matrix derivative: a 1-year prospective study. *J Periodontol.* 2005;76(6):899–907.
83. Del Pizzo M, et al. Coronally advanced flap with or without enamel matrix derivative for root coverage: a 2-year study. *J Clin Periodontol.* 2005;32:1181–1187.

84. Cueva MA, et al. A comparative study of coronally advanced flaps with and without the addition of enamel matrix derivative in the treatment of marinal tissue recession.
J Periodontol. 2004;75:949–956.
85. Nemcovsky CE, et al. A multicenter comparative study of two root coverage procedures: coronally advanced flap with addition of enamel matrix proteins and subpedicle connective tissue graft.
J Periodontol. 2004;75:600–607.
86. Abbas F, et al. Surgical treatment of gingival recessions using Emdogain gel: clinical procedure and case reports.
Int J Periodontics Restorative Dent. 2003;23:607–613.
87. McGuire MK, et al. Evaluation of human recession defects treated with coronally advanced flaps and either enamel matrix derivative or connective tissue. Part 1: comparison of clinical parameters.
J Periodontol. 2003;74:1110–1125.
88. McGuire MK, et al. Evaluation of human recession defects treated with coronally advanced flaps and either enamel matrix derivative or connective tissue. Part 2: histological evaluation.
J Periodontol. 2003;74:1126–1135.
89. Berlucchi I, et al. Enamel matrix proteins (Emdogain) in combination with coronally advanced flap or subepithelial connective tissue graft in the treatment of shallow gingival recessions.
Int J Periodontics Restorative Dent. 2002;22(6):583–593.
90. Carnio J, et al. Histological evaluation of 4 cases of root coverage following a connective tissue graft combined with an enamel matrix derivative preparation.
J Periodontol. 2002;73:1534–1543.
91. Hägewald S, et al. Comparative study of Emdogain and coronally advanced flap technique in the treatment of human gingival recessions.
J Clin Periodontol. 2002;29:35–41.
92. Rasperini G, et al. Clinical and histologic evaluation of human gingival recession treated with a subepithelial connective tissue graft and enamel matrix derivative (Emdogain): a case report.
Int J Periodontics Restorative Dent. 2000;20:269–275.
93. Heijl L. Periodontal regeneration with enamel matrix derivative in one human experimental defect. A case report.
J Clin Periodontol. 1997;24:693–696.

5 STRAUMANN® EMDOGAIN CON MATERIAL PARA INJERTO ÓSEO

En el tratamiento de defectos intraóseos amplios, ocasionalmente se considera la posibilidad de proporcionar soporte mecánico a los tejidos blandos. Algunos profesionales clínicos han referido el uso de Straumann® Emdogain en combinación con diferentes materiales sustitutos del hueso para ofrecer apoyo estructural a los tejidos blandos en defectos grandes⁹⁴⁻¹²⁰. Straumann® Emdogain PLUS combina las propiedades regeneradoras de Straumann® Emdogain con el apoyo estructural del material osteoconductor Straumann® BoneCeramic.

94. Guida L, et al. Effect of autogenous cortical bone particulate in conjunction with enamel matrix derivative in the treatment of periodontal intraosseous defects. *J Periodontol.* 2007;78(2):231-238.
95. Bokan I, et al. Primary flap closure combined with Emdogain alone or Emdogain and Cerasorb in the treatment of intrabony defects. *J Clin Periodontol.* 2006;33:885-893.
96. Trombelli L, et al. Autogenous bone graft in conjunction with enamel matrix derivative in the treatment of deep periodontal intra-osseous defects: a report of 13 consecutively treated patients. *J Clin Periodontol.* 2006;33(1):69-75.
97. Kuru B, et al. Enamel matrix derivative alone or in combination with a bioactive glass in wide intrabony defects. *Clin Oral Investig.* 2006;10:227-234.
98. Döri F, et al. Clinical evaluation of an enamel matrix protein derivative combined with either a natural bone mineral or beta-tricalcium phosphate. *J Periodontol.* 2005;76(12):2236-2243. Links.
99. Murai M, et al. Effects of the enamel matrix derivative and beta-tricalcium phosphate on bone augmentation within a titanium cap in rabbit calvarium. *J Oral Sci.* 2005;47(4):209-217.
100. Sculean A, et al. Clinical and histologic evaluation of an enamel matrix protein derivative combined with a bioactive glass for the treatment of intrabony periodontal defects in humans. *Int J Periodontics Restorative Dent.* 2005;25:139-147.
101. Sculean A, et al. Healing of human intrabony defects following regenerative periodontal therapy with an enamel matrix protein derivative alone or combined with a bioactive glass. A controlled clinical study. *J Clin Periodontol.* 2005;32(1):111-117.
102. Donos N, et al. Effect of GBR in combination with deproteinized bovine bone mineral and/or enamel matrix proteins on the healing of critical-size defects. *Clin Oral Implants Res.* 2004;15(1):101-111.
103. Parashis A, et al. Clinical and radiographic comparison of three regenerative procedures in the treatment of intrabony defects. *Int J Periodontics Restorative Dent.* 2004;24(1):81-90.
104. Sculean A, et al. Human histologic evaluation of an intrabony defect treated with enamel matrix derivative, xenograft, and GTR. *Int J Periodontics Restorative Dent.* 2004;24:326-333.
105. Cochran DL, et al. Periodontal regeneration with a combination of enamel matrix proteins and autogenous bone grafting. *J Periodontol.* 2003;74(9):1269-1281.

106. Zucchelli G, et al. Enamel matrix proteins and bovine porous bone mineral in the treatment of intrabony defects: a comparative controlled clinical trial. *J Periodontol.* 2003;74(12):1725–1735.
107. Sculean A, et al. Clinical and histologic evaluation of human intrabony defects treated with an enamel matrix protein derivative combined with a bovine-derived xenograft. *Int J Periodontics Restorative Dent.* 2003;23(1):47–55.
108. Nozawa T, et al. Connective tissue-bone onlay graft with enamel matrix derivative for treatment of gingival recession: a case report. *Int J Periodontics Restorative Dent.* 2002;22(6):559–565.
109. Caffesse RG, et al. Regeneration of soft and hard tissue periodontal defects. *Am J Dent.* 2002;15(5):339–345. Review.
110. Rosen PS, Reynolds MA. A retrospective case series comparing the use of demineralized freeze-dried bone allograft and freeze-dried bone allograft combined with enamel matrix derivative for the treatment of advanced osseous lesions. *J Periodontol.* 2002;73(8):942–949.
111. Velasquez-Plata D, et al. Clinical comparison of an enamel matrix derivative used alone or in combination with a bovine-derived xenograft for the treatment of periodontal osseous defects in humans. *J Periodontol.* 2002;73(4):433–440. Erratum in: *J Periodontol.* 2002;73(6):684.
112. Sculean A, et al. Clinical evaluation of an enamel matrix protein derivative combined with a bioactive glass for the treatment of intrabony periodontal defects in humans. *J Periodontol.* 2002;73:401–408.
113. Sculean A, et al. Clinical evaluation of an enamel matrix protein derivative (Emdogain) combined with a bovine-derived xenograft (Bio-Oss) for the treatment of intrabony periodontal defects in humans. *Int J Periodontics Restorative Dent.* 2002;22:259–267.
114. Venezia E, et al. [The use of enamel matrix derivative in periodontal therapy]. Review. Hebrew. *Refuat Hapeh Vehashinayim.* 2002;19(3):19–34,88.
115. Froum S, et al. The use of enamel matrix derivative in the treatment of periodontal osseous defects: a clinical decision tree based on biologic principles of regeneration. *Int J Periodontics Restorative Dent.* 2001;21(5):437–449. Review.
116. Lekovic V, et al. The use of bovine porous bone mineral in combination with enamel matrix proteins or with an autologous fibrinogen/fibronectin system in the treatment of intrabony periodontal defects in humans. *J Periodontol.* 2001;72(9):1157–1163.
117. Camargo PM, et al. The effectiveness of enamel matrix proteins used in combination with bovine porous bone mineral in the treatment of intrabony defects in humans. *J Clin Periodontol.* 2001;28:1016–1022.
118. Heard RH, Mellonig JT. Regenerative materials: an overview. *Alpha Omegan.* 2000;93(4):51–58. Review.
119. Karring T. Regenerative periodontal therapy. *J Int Acad Periodontol.* 2000;2(4):101–109. Review.
120. Lekovic V, et al. A comparison between enamel matrix proteins used alone or in combination with bovine porous bone mineral in the treatment of intrabony periodontal defects in humans. *J Periodontol.* 2000;71(7):1110–1116.

www.straumann.com

International Headquarters

Institut Straumann AG
Peter Merian-Weg 12
CH-4002 Basel, Switzerland
Phone +41 (0)61 965 11 11
Fax +41 (0)61 965 11 01
